A magnetic resonance imaging study to assess the short-term physical modifications of the disease process after SB-061 treatment
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs SB 061 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms MODIFY-MRI
- 25 Apr 2019 According to a Symic Bio media release, the latest financing will be utilized to advance Symic Bios disease-modifying osteoarthritis drug, SB-061, into this global phase 2b trial which is expected to be started in the latter half of 2019.
- 27 Aug 2017 New trial record
- 23 Aug 2017 According to a SYMIC Biomedical media release, the company expects to report top-line results from the study in early 2018.